KFAS
MDGL icon

Keating Financial Advisory Services’s Madrigal Pharmaceuticals MDGL Stock Holding History

Keating Financial Advisory Services’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4K Buy
25
+4
+19% +$2.05K ﹤0.01% 1139
2026
Q1 		$11K Buy
21
+11
+110% +$5.25K ﹤0.01% 1100
2025
Q4 		$5.82K Buy
+10
New +$5.11K ﹤0.01% 1240

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Keating Financial Advisory Services's MDGL Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Madrigal Pharmaceuticals (MDGL) stake by 19% in Q2 2026, buying an estimated $2.05K and bringing the position to 25 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

Keating Financial Advisory Services first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Keating Financial Advisory Services held 25 shares of Madrigal Pharmaceuticals worth $13.4K as of Q2 2026.
  • Keating Financial Advisory Services bought 4 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.05K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1139 holding.
  • Keating Financial Advisory Services first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.